Want to join the conversation?
Drug company $MRK said that they have revealed the results from the KEYNOTE-010 study of KEYTRUDA (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC). KEYNOTE-010 is a randomized, pivotal Phase 2/3 trial comparing 2 doses of KEYTRUDA (2mg/kg dose or 10mg/kg dose, each given every 3 weeks), to docetaxel, a commonly used chemotherapy.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?